Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

  • ID: 4542979
  • Drug Pipelines
  • 2186 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 3SBio Inc
  • Biogen Inc
  • Daiichi Sankyo Co Ltd
  • Immunomedics Inc
  • Merck KGaA
  • Respiratorius AB
  • MORE
Non-Hodgkin Lymphoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

This latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 4, 30, 160, 136, 1, 5, 126, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 19, 22, 17 and 4 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBio Inc
  • Biogen Inc
  • Daiichi Sankyo Co Ltd
  • Immunomedics Inc
  • Merck KGaA
  • Respiratorius AB
  • MORE
Introduction

Non-Hodgkin Lymphoma - Overview

Non-Hodgkin Lymphoma - Therapeutics Development

Non-Hodgkin Lymphoma - Therapeutics Assessment

Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development

Non-Hodgkin Lymphoma - Drug Profiles

Non-Hodgkin Lymphoma - Dormant Projects

Non-Hodgkin Lymphoma - Discontinued Products

Non-Hodgkin Lymphoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AlfaSigma SpA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Aptevo Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Autolus Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bantam Pharmaceutical LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Biogen Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Brickell Biotech Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CARsgen Therapeutics Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellestia Biotech AG, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cerenis Therapeutics Holding SA, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Cielo Therapeutics Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2018

Non-Hodgkin Lymphoma - Pipeline by Corvus Pharmaceuticals Inc, H1 2018

Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics Inc, H1 2018

List of Figures

Number of Products under Development for Non-Hodgkin Lymphoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3SBio Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • ACEA Biosciences Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Affimed GmbH
  • Affitech A/S
  • Agios Pharmaceuticals Inc
  • Aileron Therapeutics Inc
  • AlfaSigma SpA
  • Allinky Biopharma
  • Altor BioScience Corp
  • Amgen Inc
  • Angimmune LLC
  • Aptevo Therapeutics Inc
  • arGEN-X BV
  • Ariad Pharmaceuticals Inc
  • ArQule Inc
  • Arrien Pharmaceuticals LLC
  • Arven Ilac
  • Asana BioSciences LLC
  • Aslan Pharmaceuticals Pte Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Autolus Ltd
  • Bantam Pharmaceutical LLC
  • Bayer AG
  • BeiGene Ltd
  • Bellicum Pharmaceuticals Inc
  • Bio-Path Holdings Inc
  • Biocon Ltd
  • Biogen Inc
  • BioInvent International AB
  • BioLineRx Ltd
  • BioSight Ltd
  • Biothera Pharmaceutical Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Brickell Biotech Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • CARsgen Therapeutics Ltd
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Cell Medica Ltd
  • Cell Source Inc
  • Cell>Point LLC
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cellectis SA
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Celltrion Inc
  • Cellular Biomedicine Group Inc
  • Centrose LLC
  • Cerenis Therapeutics Holding SA
  • CerRx Inc
  • Chipscreen Biosciences Ltd
  • Cielo Therapeutics Inc
  • Clevexel Pharma SAS
  • Corvus Pharmaceuticals Inc
  • CrystalGenomics Inc
  • CSPC Pharmaceutical Group Limited
  • CTI BioPharma Corp
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Denovo Biopharma LLC
  • Dynavax Technologies Corp
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Epizyme Inc
  • Erytech Pharma SA
  • Eureka Therapeutics Inc
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Formula Pharmaceuticals Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corporation
  • Galderma SA
  • Gamida Cell Ltd
  • Genentech Inc
  • Genor BioPharma Co Ltd
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Grupo Ferrer Internacional SA
  • GT Biopharma Inc
  • H3 Biomedicine Inc
  • Heidelberg Pharma AG
  • Hualan Biological Engineering Inc
  • Hutchison MediPharma Ltd
  • IGF Oncology LLC
  • Ignyta Inc
  • Immune Design Corp
  • ImmunGene Inc
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immunomet Therapeutics Inc
  • Immunovaccine Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Innate Pharma SA
  • Innovent Biologics Inc
  • IO Biotech ApS
  • Japan Tobacco Inc
  • JHL Biotech Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • K-Stemcell Co Ltd
  • KAHR medical Ltd
  • Kainos Medicine Inc
  • Karyopharm Therapeutics Inc
  • Kiromic Inc
  • Kite Pharma Inc
  • Klyss Biotech Inc
  • Komipharm International Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Leadiant Biosciences Inc
  • Les Laboratoires Servier SAS
  • LFB SA
  • Loxo Oncology Inc
  • LSK BioPartners Inc
  • Mabion SA
  • MacroGenics Inc
  • Meabco AS
  • MedImmune LLC
  • Medivir AB
  • MEI Pharma Inc
  • MENTRIK Biotech LLC
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • Miragen Therapeutics Inc
  • Mirati Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • Molecular Templates Inc
  • Moleculin Biotech Inc
  • Morphogenesis Inc
  • MorphoSys AG
  • NantKwest Inc
  • NBE-Therapeutics AG
  • Nerviano Medical Sciences Srl
  • Neumedicines Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nordic Nanovector ASA
  • NovaLead Pharma Pvt Ltd
  • Novartis AG
  • NovImmune SA
  • Oncobiologics Inc
  • Onconova Therapeutics Inc
  • Oncopeptides AB
  • Oncovir Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Oxford BioTherapeutics Ltd
  • Patrys Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Philogen SpA
  • PIQUR Therapeutics AG
  • Plexxikon Inc
  • Portola Pharmaceuticals Inc
  • Prescient Therapeutics Ltd
  • Protheragen Inc
  • Quimatryx SL
  • Rafael Pharmaceuticals Inc
  • Refuge Biotechnologies Inc
  • Regeneron Pharmaceuticals Inc
  • Respiratorius AB
  • Rhizen Pharmaceuticals SA
  • Richter Gedeon Nyrt
  • Sandoz International GmbH
  • Sanofi
  • Sareum Holdings Plc
  • Seattle Genetics Inc
  • Selvita SA
  • Senhwa Biosciences Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Henlius Biotech Co Ltd
  • Shanghai Pharmaceutical Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Sierra Oncology Inc
  • Solasia Pharma KK
  • Soligenix Inc
  • Spectrum Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • Sunesis Pharmaceuticals Inc
  • Supratek Pharma Inc
  • Surface Oncology Inc
  • Sutro Biopharma Inc
  • Syndax Pharmaceuticals Inc
  • TaiGen Biotechnology Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • Taiwan Liposome Company Ltd
  • Takara Bio Inc
  • TCR2 Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
  • TG Therapeutics Inc
  • TRACON Pharmaceuticals Inc
  • Transgene Biotek Ltd
  • Transgene SA
  • Trillium Therapeutics Inc
  • Triphase Accelerator Corp
  • Trovagene Inc
  • TTY Biopharm Company Ltd
  • United BioPharma Inc
  • Unum Therapeutics Inc
  • Verastem Inc
  • Vivolux AB
  • Vyriad Inc
  • Xencor Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll